Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis

2004, Bone health and osteoporosis: a report of the Surgeon General, Washington, DC: U.S. Department of Health and Human Services, Public Health Service, Office of the Surgeon General

Cosman, 2008, Parathyroid hormone treatment for osteoporosis., Curr Opin Endocrinol Diabetes Obes, 15, 495, 10.1097/MED.0b013e32831a46d6

Miller, 2008, Safety of parathyroid hormone for the treatment of osteoporosis., Curr Osteoporos Rep, 6, 12, 10.1007/s11914-008-0003-y

Black, 2006, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial., JAMA, 296, 2927, 10.1001/jama.296.24.2927

Ensrud, 2004, Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension., J Bone Miner Res, 19, 1259, 10.1359/JBMR.040326

Black, 2005, One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis., N Engl J Med, 353, 555, 10.1056/NEJMoa050336

Kaufman, 2005, Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy., Osteoporos Int, 16, 510, 10.1007/s00198-004-1713-3

Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis., N Engl J Med, 349, 1216, 10.1056/NEJMoa035725

Rosenthal, 1985, Quantitative computed tomography for spinal density measurement. Factors affecting precision., Invest Radiol, 20, 306, 10.1097/00004424-198505000-00014

Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis., N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904

Orwoll, 2003, The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis., J Bone Miner Res, 18, 9, 10.1359/jbmr.2003.18.1.9

Lindsay, 2004, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis., Arch Intern Med, 164, 2024, 10.1001/archinte.164.18.2024

Adami, 2008, Effect of raloxifene after recombinant teriparatide [hPTH(1–34)] treatment in postmenopausal women with osteoporosis., Osteoporos Int, 19, 87, 10.1007/s00198-007-0485-y

Prince, 2005, Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment., J Bone Miner Res, 20, 1507, 10.1359/JBMR.050501

Khosla, 2001, Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men., J Clin Endocrinol Metab, 86, 3555, 10.1210/jcem.86.8.7736

Khosla, 2008, Osteoporosis in men., Endocr Rev, 29, 441, 10.1210/er.2008-0002

Cosman, 1993, Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers., Ann Intern Med [Erratum (1994) 120:698], 118, 337, 10.7326/0003-4819-118-5-199303010-00003

Joborn, 1991, Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement., Clin Endocrinol (Oxf), 34, 335, 10.1111/j.1365-2265.1991.tb00302.x

Leder, 2001, Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men., J Clin Endocrinol Metab, 86, 511

Lee, 2006, Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men., J Clin Endocrinol Metab, 91, 1069, 10.1210/jc.2005-2495

Tsai, 1989, Bone responsiveness to parathyroid hormone in normal and osteoporotic postmenopausal women., J Clin Endocrinol Metab, 69, 1024, 10.1210/jcem-69-5-1024

Finkelstein, 1999, Effects of gonadal suppression on the regulation of parathyroid hormone and 1,25-dihydroxyvitamin D secretion in women., J Clin Endocrinol Metab, 84, 2151

Venken, 2008, Sex hormones, their receptors and bone health., Osteoporos Int, 19, 1517, 10.1007/s00198-008-0609-z

Zaidi, 2007, Proresorptive actions of FSH and bone loss., Ann NY Acad Sci, 1116, 376, 10.1196/annals.1402.056

Bikle, 2002, Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone., J Bone Miner Res, 17, 1570, 10.1359/jbmr.2002.17.9.1570

Canalis, 1989, Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures., J Clin Invest, 83, 60, 10.1172/JCI113885

Brabant, 2007, Normal levels of serum IGF-I: determinants and validity of current reference ranges., Pituitary, 10, 129, 10.1007/s11102-007-0035-9

O'Connor, 1998, Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men, J Gerontol A Biol Sci Med Sci, 53, M176, 10.1093/gerona/53A.3.M176

Lauretani, 2008, Longitudinal changes in BMD and bone geometry in a population-based study., J Bone Miner Res, 23, 400, 10.1359/jbmr.071103

Riggs, 2004, Population-based study of age and sex differences in bone volumetric density, size, geometry, and structure at different skeletal sites., J Bone Miner Res, 19, 1945, 10.1359/jbmr.040916